<ul>
	<li>Patients with hypersensitivity to pheniramine or any other ingredient (eg. Methyl hydroxybenzoate or propyl hydroxybenzoate in the syrup).</li>
	<li>Patients with symptomatic prostatic hypertrophy.</li>
	<li>Patients receiving MAO-inhibitor therapy.</li>
	<li>Newborn and premature infants.</li>
</ul>